“Applikon Biotechnology is committed to continuing to deliver products and software innovations that bring significant efficiencies to our customers while simplifying operations in the biotech laboratories,” said Arthur Oudshoorn, CEO of Applikon Biotechnology. “We believe that the acquisition of the biotech portfolio of HaloteC Instruments will accelerate our development of bioreactor software solutions, allowing our customers to greatly improve the efficiency and performance of their R&D departments. The instrumentation for the food and biofuel industry that HaloteC has developed extends the products offering Applikon Biotechnology for these industries. Organizations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes. The advanced software solutions that HaloteC Instruments has developed for these types of applications allow the researcher to compare large data sets and easily see relations between various parameters. The software and instrumentation excel in ease of operation and robust design and will contribute to the increasing market share of Applikon Biotechnology.”
As part of its strategy to deliver an advanced datacenter for biotech processes, Applikon Biotechnology continues to invest and innovate to extend the benefits of instrumentation and software solutions for the bioprocess industry.
“Applikon Biotechnology and HaloteC Instruments share a highly aligned vision to remove complexity and increase efficiencies in the biotechnology based R&D laboratories,” said Emo van Halsema, CEO, HaloteC. “We are excited to combine forces with Applikon to provide customers a more cost-effective, efficient, and easy to operate solution for process development and optimization.”
Terms of the acquisition were not disclosed.
